|Home||» Products||» Anticancer Injectables||» Zolendronic Acid Injection|
We are a prominent firm in this domain, instrumental in providing quality approved Zolendronic Acid Injection. This injection is formulated by our skilled professionals using premium grade chemicals at advanced processing unit. The offered injection is used for treating high levels of calcium in the blood that may be caused by cancer. Additionally, the provided Zolendronic Acid Injection can be availed from us in various packaging according to need of clients at pocket friendly rates.
|Composition :|| Each vial contains:
Zoledronic acid monohydrate 4.264mg
eq to Zoledronic acid 4mg
|Indication :||Zoledronic acid is indicated for the treatment of hypercalcemia, multiple myeloma, bone metastases, osteoporosis in men and women.|
|Dosage :-||Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. The maximum recommended dose of Zoledronic acid in hypercalcemia of malignancy (albumin-corrected serum calcium greater than or equal to 12 mg/dL [3.0 mmol/L]) is 4 mg. The 4-mg dose must be given as a single-dose intravenous infusion over no less than 15 minutes. Patients who receive Zoledronic acid should have serum creatinine assessed prior to each treatment.|
|Contra Indications:-||Hypersensitivity reactions including rare cases of urticaria and angioedema, and very rare cases of anaphylactic reaction/shock have been reported.|
|Precautions:-||Patients with hypercalcemia of malignancy must be adequately rehydrated prior to administration of Zoledronic acid, treatment is not recommended in patients with bone metastases with severe renal impairment and in hepatic impairement.|
|Pharmacological Action:||The principal pharmacological action of Zoledronic acid is inhibition of bone resorption. In vitro, zoledronic acid inhibits osteoclastic activity and induces osteoclast apoptosis. Zoledronic acid also blocks the osteoclastic resorption of mineralized bone and cartilage through its binding to bone. Zoledronic acid inhibits the increased osteoclastic activity and skeletal calcium release induced by various stimulatory factors released by tumors.|
|Drug interaction:||In-vitro studies indicate that Zoledronic acid is approximately 22% bound to plasma proteins. In-vitro studies also indicate that Zoledronic acid does not inhibit microtonal CYP450 enzymes. In-vivo studies showed that Zoledronic acid is not metabolized, and is excreted into the urine as the intact drug.|
|Adverse effect:||Administration of Zoledronic acid 4 mg given as a 5-minute intravenous infusion has been shown to result in an increased risk of renal toxicity The most frequently observed adverse events were fever, nausea, constipation, anemia, and dyspnea. rash, pruritus.|
|Storage:||Store at 25Â°C (77Â°F); excursions permitted to 15-30Â°C (59-86Â°F).|
HEALTH BIOTECH LTD. All Rights Reserved.